XBP1 and cancer: To this end, we combined AZD1775 with MKC8866, a specific IRE1α RNase inhibitor previously described in multiple cancer models.[10, 15, 24] We first verified that MKC8866 robustly suppressed XBP1 splicing in OVCAR8 cells (Figure S6A, Supporting Information).